Highlights
- Severe obesity (Class 3, BMI ≥40 kg/m²) is associated with a 3.0-fold increased risk of heart failure and a 2.8-fold increased risk of atrial fibrillation compared to normal weight.
- Women with severe obesity experience higher relative increases in the risk of stroke, total CVD, and all-cause mortality compared to men in the same BMI categories.
- While obesity is a robust risk factor for most cardiovascular outcomes, stroke risk in men did not show a linear increase with higher BMI categories, whereas in women, the risk remained significantly elevated but plateaued.
- Adjusting for traditional clinical risk factors does not eliminate the increased risk associated with high BMI, suggesting independent pathophysiological mechanisms related to adiposity.
Background
The global prevalence of obesity has reached pandemic proportions, yet the nuances of its cardiovascular impact—particularly across the severe obesity spectrum—remain a subject of intense clinical scrutiny. While the link between a high Body Mass Index (BMI) and atherosclerotic cardiovascular disease (ASCVD) is well-documented, the specific hazard ratios for Class 2 (BMI 35 to <40.0 kg/m²) and Class 3 (BMI ≥40 kg/m²) obesity across diverse populations have been less clear. Furthermore, whether biological sex modulates these risks across nearly a dozen distinct cardiovascular outcomes has historically been under-investigated in large-scale, harmonized cohorts. Understanding these relationships is critical for refining risk stratification and personalizing therapeutic interventions in an era where metabolic health management is increasingly centralized in cardiovascular preventative care.
Key Content
Methodological Framework of the Cross-Cohort Collaboration
The Cross-Cohort Collaboration represents a significant methodological advancement in epidemiological research. By integrating data from 21 distinct cohorts (enrolled between 1948 and 2015), the study by Dardari et al. (PMID: 41674444) analyzed 289,875 participants with a mean age of 60.3 years. Notably, the cohort was predominantly female (79.2%), providing robust statistical power to detect sex-specific interactions. The study utilized multivariable Cox proportional hazard models with restricted cubic splines to map the relationship between BMI and nine adjudicated outcomes: myocardial infarction (MI), stroke, heart failure (HF), atrial fibrillation (AF), coronary heart disease (CHD), total CVD, CHD mortality, CVD mortality, and all-cause mortality.
The Hierarchy of Cardiovascular Risk: Heart Failure and Atrial Fibrillation
The most striking findings of the collaboration were the disproportionate risks of heart failure and atrial fibrillation. For individuals with Class 3 obesity, the Hazard Ratio (HR) for HF reached 3.0 (95% CI, 2.7–3.2), and for AF, the HR was 2.8 (95% CI, 2.5–3.1). These results underscore that while obesity contributes to ischemia-related diseases, its impact on cardiac structure and electrophysiology (leading to HF and AF) is even more profound. The persistent risk after adjustment for traditional factors suggests that adipose-driven inflammation, hemodynamic volume overload, and epicardial fat deposition play direct roles in the pathogenesis of non-ischemic cardiovascular events.
Sex-Specific Risk Profiles and the Stroke Disparity
One of the most clinically relevant findings involves the sex-interaction analysis. Women with severe obesity demonstrated a higher relative hazard for stroke, total CVD, and all-cause mortality compared to men. For instance, in men, no significant trend was observed between increasing BMI categories and stroke risk (P trend = 0.49). Conversely, in women, while the risk of stroke plateaued in the higher obesity subclasses, it remained significantly elevated compared to women of normal weight. This divergence suggests that the physiological response to excess adiposity may differ by sex, potentially due to hormonal influences on fat distribution (visceral vs. subcutaneous) and vascular reactivity.
Integration with Metabolic Health and Therapeutics
The findings from the Cross-Cohort Collaboration coincide with a shift toward metabolic health stratification (PMID: 41421836). As global obesity forecasts suggest a rising burden, identifying the “metabolically unhealthy” phenotype becomes paramount. Modern pharmacotherapy, such as oral small-molecule GLP-1 receptor agonists (PMID: 41421831), offers a promising avenue for addressing the BMI-associated risk evidenced in the Dardari study. These agents not only promote weight loss but also exert independent cardiovascular benefits, potentially mitigating the specific risks of HF and AF highlighted in this review. Furthermore, nutritional interventions like the EAT-Lancet diet (PMID: 41692025) emphasize that while sustainable plant-based diets can ensure nutrient adequacy, their role in weight management remains a cornerstone of CVD prevention.
Expert Commentary
From a clinical perspective, the Dardari et al. study serves as a rigorous reminder that BMI is not a monolithic risk factor. The extreme hazards for HF and AF observed in Class 3 obesity suggest that weight management should be prioritized as a primary prevention strategy for these conditions, rather than just as a secondary concern after managing hypertension or dyslipidemia. The sex differences in stroke and mortality risks are particularly provocative; they suggest that traditional risk calculators may underestimate the relative danger of obesity in women. However, it is important to acknowledge the limitations of BMI as a measure of adiposity, as it does not distinguish between lean mass and fat mass, nor does it account for fat distribution. Future research should prioritize the use of waist-to-hip ratios or imaging-based adiposity measures alongside longitudinal outcomes to further clarify these biological mechanisms.
Conclusion
The Cross-Cohort Collaboration provides definitive evidence that higher BMI, particularly in the range of Class 2 and Class 3 obesity, is a potent and often independent driver of cardiovascular morbidity and mortality. With heart failure and atrial fibrillation showing the strongest associations, clinical focus must shift toward aggressive weight intervention. The discovery of sex-specific hazard ratios for stroke and mortality opens new doors for personalized risk assessment. As we look toward 2026 and beyond, the integration of potent weight-loss pharmacotherapy and standardized nutritional frameworks will be essential in curbing the cardiovascular consequences of the global obesity epidemic.
References
- Dardari ZA, et al. Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. Circulation. 2026. PMID: 41674444.
- Esson K, et al. Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity. Lancet. 2026. PMID: 41421831.
- Johansson I, et al. Nutritional adequacy of the EAT-Lancet diet: a Swedish population-based cohort study. Lancet Planet Health. 2027. PMID: 41692025.
- Müller MJ, et al. The need for metabolic health stratification in global obesity forecasts. Lancet. 2026. PMID: 41421836.